591767-62-3

Basic information

• Product Name: Isoquinoline, 6-methoxy-, 2-oxide (9CI)
• Synonyms: Isoquinoline, 6-methoxy-, 2-oxide (9CI);6-Methoxyisoquinoline 2-oxide
• CAS NO: 591767-62-3
• Molecular Formula: C10H9NO2
• Molecular Weight: 175.18396
• Product Categories: METHOXY
• Mol File: 591767-62-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Isoquinoline, 6-methoxy-, 2-oxide (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Isoquinoline, 6-methoxy-, 2-oxide (9CI)(591767-62-3)
• EPA Substance Registry System: Isoquinoline, 6-methoxy-, 2-oxide (9CI)(591767-62-3)

Safety Data

• Hazardous Substances Data: 591767-62-3(Hazardous Substances Data)

Upstream product

• 52986-70-6 6-methoxyisoquinoline 
• 2311-91-3 monoperoxyphthalic acid 
• 54879-77-5 N-(4-methoxybenzyl)aminoacetaldehyde dimethyl acetal 
• 123-11-5 4-methoxy-benzaldehyde 
• 42923-77-3 6-methoxy-1,2,3,4-tetrahydro-isoquinoline 

Relevant articles and documents

Cu(II)-Catalyzed Construction of Heterobiaryls using 1-Diazonaphthoquinones: A General Strategy for the Synthesis of QUINOX and Related P,N Ligands

An efficient and straightforward method was developed for the synthesis of heterobiaryls using easily available N-oxides and diazonaphthoquinones under cheap Cu(II) catalysis. The developed method offered QUINOX and related congeners in a simple manner. A wide scope of important heterobiaryls was achieved with high site selectivity. The synthesized naphthols were transformed into the privileged related P,N ligands. Suitable resolution methods can directly afford the corresponding axially chiral heterobiaryls.

SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME

The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient.

New substituted isoquinoline and isoquinolinone derivatives

The invention relates to 6-substituted isoquinoline and isochinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.